Investor Relations

Syneron Medical Ltd (ELOS) IR Room

Syneron Medical Ltd. Announces Availability of its Annual Report on Form 20-F through its Website

03/23/2017

IRVINE, Calif., March 23, 2017 /PRNewswire/ -- Syneron Medical Ltd. (NASDAQ: ELOS), a leading global aesthetic device company, today announced that its Annual Report on Form 20-F, containing audited consolidated financial statements for the year ended December 31, 2016, as filed with the Securities and Exchange Commission on March 23, 2017, is available on its website (www.syneron.com). Shareholders may receive a hard copy of the annual report free of charge upon request. This press release is being issued pursuant to NASDAQ Listing Rule 5250(d)(1)(C).

About Syneron Candela:
Syneron Candela is a leading global aesthetic device company with a comprehensive product portfolio and a global distribution footprint.  The Company's technology enables physicians to provide advanced solutions for a broad range of medical-aesthetic applications including body contouring, hair removal, wrinkle reduction, tattoo removal, women's intimate wellness treatments, improving the skin's appearance through the treatment of superficial benign vascular and pigmented lesions, and the treatment of acne, leg veins and cellulite. The Company has a wide portfolio of trusted, leading products including UltraShape, VelaShape, GentleLase, VBeam Perfecta, PicoWay, CO2RE, CO2RE Intima, Profound and elōs Plus.

Founded in 2000, the company markets, services and supports its products in 86 countries.  It has offices in North America, France, Germany, Italy, Portugal, Spain, UK, Australia, China, Japan, and Hong Kong and distributors worldwide.

SOURCE Syneron Medical Ltd.

For further information: Syneron Contacts: Hugo Goldman, Chief Financial Officer, Syneron Medical, +972-73-2442200, Email: hugo.goldman@syneron.com; Zack Kubow, The Ruth Group, 646-536-7020, Email: zkubow@theruthgroup.com

Price Data
NASDAQELOS
NASDAQELOS

print email rss